Carbamazepine a pain reliever and an anticonvulsant agent with use in MS.

Carbamazepine a pain reliever and an anticonvulsant agent with use in MS.

Epitol, Novartis and Tegretol are all brand names for Carbamazepine a pain reliever and an anticonvulsant agent used in treating such disorders as Trigeminal Neuralgia in Multiple Sclerosis, Epilepsy and Mania Disorders.

Carbamazepine is not an ordinary pain killer and should always be taken under direction from your physician. It is likely that the doctor will monitor your condition while under treatment to ensure no adverse reaction to the drug.

Fampridine – SR a pharmaceutical, mobility aid for MS patients

Fampridine – SR a pharmaceutical, mobility aid for MS patients

Fampridine has been found to improve impulse conduction in nerve fibres with myelin damage. Improved nerve conduction improves mobility.

On 25th September 2006, Acorda Therapeutics announced positive results from it’s phase 3 clinical trials. The trials were a double-blind study where over 34% of patients on Fampridine showed an improvement in a Timed 25 foot Walk.

Aricept (Donepezil), a drug for Alzheimer’s Disease may aid memory in MS

Aricept (Donepezil), a drug for Alzheimer’s Disease may aid memory in MS

An Alzheimer’s Disease drug, Aricept, may improve memory in patients with Multiple Sclerosis brain fog. Help MS patients to meet the cognitive challenges of their daily lives.

In a Neurology editorial, P. Murali Doraiswamy, MD, of Duke University Medical Center and Stephen Rao, PhD, of the Medical College of Wisconsin, agree. Praising Krupp’s study as “a major advance,”

Novantrone an antineoplastic suppresses the activity of T cells, thought to lead to attack on myelin

Novantrone an antineoplastic suppresses the activity of T cells, thought to lead to attack on myelin

Novantrone belongs to the general group of medicines called antineoplastics. Prior to its approval for use in MS, it was used only to treat certain cancers.

Based on findings from these studies, the FDA approved Novantrone in October, 2000 for reducing neurologic disability and/or the frequency of clinical relapses (attacks)

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close